• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Bone Therapeutics, Rigenerand Ink Cell Therapy Deal

    NovaQuest Private Equity Acquires CoreRx

    JS Bio and Etta Biotech Advancing Partnership

    Intravacc Completes Project for Provention Bio’s Vax Candidate

    Lonza to Exit Pharma Softgels and Liquid-Filled Hard Capsules
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Lonza to Exit Pharma Softgels and Liquid-Filled Hard Capsules

    Cognate BioServices Announces Major Expansion

    Sanofi Unveils EUROAPI as Name of New European API Company

    Precision Medicine Group Acquires Project Farma

    Cytiva Delivers Modular Biologics Factory to Lonza
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe

    Schreiner MediPharm Joins DoseID Consortium
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    The Future of Clinical Trials Series: Part I

    JS Bio and Etta Biotech Advancing Partnership

    Intravacc Completes Project for Provention Bio’s Vax Candidate

    Drug Development For Startups

    Metrion, LifeArc Extend Neuroscience Alliance
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

    CDMO Cognate BioServices Teams Up with L7 Informatics

    The Wasdell Group Earns ISO 13485 Certification
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Flow Sciences

    Aphena Pharma Solutions

    Adare Pharma Solutions

    Syngene

    Reed-Lane
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Emergent BioSolutions

    Cytovance Biologics

    Aphena Pharma Solutions

    Alcami

    Syngene
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    CRO Consolidations: A Boon for Pharma?

    In the contract research space there is a movement towards consolidation in order to expand capabilities and reach to service

    CRO Consolidations: A Boon for Pharma?
    Related CONTENT
    • The Future of Clinical Trials Series: Part I
    • Metrion, LifeArc Extend Neuroscience Alliance
    • Virtual Clinical Trials: The Future of Dermatology Studies
    • Bioclinica Partners with Ikcon Pharma
    • Capricor, Lonza Enter CAP-1002 Development Agreement
    Craig Morgan, Head of Marketing, goBalto11.07.17
    In human clinical trials, especially Phase III, represent by far the largest part of the substantial cost1 of bringing new drugs to market. Over the last several decades as the size, complexity, length, cost and globalization of clinical trials has continued to grow, the importance of contract research organizations (CROs) to the pharmaceutical and biotech industries has increased significantly. Outsourcing has become a popular way for pharmaceutical companies to utilize on-demand services to improve operational efficiency and therapeutic expertise, cut costs, and add more extensive geographic capabilities.

    As demand for their services has intensified, the CRO industry has responded with a growing movement towards consolidation in order to expand capabilities and reach to service large global studies. Recently, there have been a number of noteworthy mergers and acquisitions (M&As):
    • InVentiv Health and INC Research merged to form one of the world’s largest CROs with net revenues estimated at $3.2 billion.2
    • Quintiles merged with IMS Health to improve trail execution using patient data, creating a company with market cap of around $18 billion.3
    • Qunitiles also recently acquired DrugDev,4 a technology company that has built one of the industry’s largest global investigator networks and data sharing platforms, and Wingspan, an eTMF solutions provider.
    • PPD acquired Acurian to gain analytics-driven feasibility capabilities.5
    • LabCorp acquired Covance for collective data resources to drive greater R&D productivity6 and recently announced its pending acquisition of the CRO Chiltern.7
    • SynteractHCR was acquired by Amulet Capital Partners.8
    • Parexel to be acquired by Pamplona Capital.9
    • PRA Health Sciences acquired Symphony Health Solutions in order to integrate healthcare analytics with their clinical research services.10
    M&A spending in the CRO industry reached $24 billion in 2016,6 and according to ISRs 2017 CRO Market Size report, the top 9 CROs now represent 60% of the market share in clinical trials.

    One of the more interesting features of this consolidation trend is private equity (PE) companies purchasing CROs.12 The proliferation of CRO purchases by PE firms in recent years is an indication that wall street understands that significant profit can be made when real improvements are made in CROs after M&As—the CRO market has in fact been one of the best performing sectors in recent years in financial circles.

    But just because CRO M&As are good for wall street, does not necessarily mean they are good for the pharmaceutical industry as a whole.

    Benefits of CRO consolidation
    Sponsors of large, global Phase III clinical trials want a competitive CRO market with plenty of quality CROs with global reach to choose from. These sponsors are also looking to form strategic partnerships and preferred provider arrangements with just a few large CROs, as this is far easier to manage.13

    From a CRO perspective, winning one large $200-300 million Phase III study can be a huge benefit for the bottom line. As a result, there is pressure within the CRO industry for mergers as a way to quickly expand reach into places like the Middle East, North Africa and parts of Asia other than China and India, in order to be attractive to large sponsors. Additionally, mergers can provide a quick way for CROs to expand their offerings beyond clinical services in order to attract business from all aspects of the drug development lifecycle.
    This M&A trend in the CRO industry provides a number of benefits for sponsors:
    • Increased scalability and geographic presence. As CROs expand their global reach through M&As, sponsors gain access to on-demand scalability for their clinical trials.
    • Access to additional therapeutic expertise and service capabilities. Many CRO mergers are driven by the desire to add additional therapeutic expertise and service capabilities to their offerings.4 As CROs expand their offerings, sponsors gain the ability to access more services from a single partner.
    • Technology improvements. The right technologies, especially for site identification, selection, and startup activities, can make a big impact in shortening clinical timelines and the overall success of a clinical trial. By providing economies of scale, CRO M&As can allow CROs to invest in technologies that significantly improve operational efficiencies and data integrity in clinical trials.
    • Cost savings. CRO M&As allow sponsors to have access to “one-stop shopping” with their CRO partners. Sponsors save money through the operational efficiencies that needing fewer partners to run their global trials provides. Additionally, cost savings in the operations of the CRO itself due to economies of scale generated by being a larger enterprise be passed on to sponsors.
    Drawbacks of CRO consolidation
    While the CRO consolidation phenomenon is overall a positive trend for the pharmaceutical industry, there are some drawbacks to consider:
    • Less business for CRO service providers. Those companies that provide services to CROs (e.g., labs, patient recruitment companies, EDC and IRT vendors, etc.) will lose business as their client’s merge.
    • Disruptions to clinical trials. There really is never a good time to accomplish a merger. The last thing any sponsor wants to hear is that the CRO that is running their trial was just bought out or is undergoing a merger. Inevitably, in-progress clinical trials will be affected by CROs mergers—labs will likely be shut down in the middle of running the trial, requiring transfer of all data, samples and knowledge to a different site.
    • Less CROs for sponsors to choose from. Presently, there are still plenty of CROs for sponsors to consider when looking for a clinical trial partner. However, if this consolidation trend continues, we may eventually reach a tipping point where there are significantly fewer options available.
    While CRO consolidation may create some disruption in the short term, having less CROs available for sponsors may ultimately provide some benefit. With less options available, pharmaceutical companies and CROs may be forced to create more long-lasting, win-win partnerships. Collaborative partnerships will inevitably lead to more operational efficiencies in the drug development process, ultimately reducing the time required to get effective therapies to patients in need.

    How do CROs compare to sponsors?
    Is this outsourcing trend justified by gains in study conduct efficiencies? The study startup phase of a trial has been receiving renewed focus from pharmaceutical companies under intense pressure to reduce timelines and abate the rising costs of drug development, as it is notoriously inefficient yet has the biggest impact on overall study timelines, budget, and operational outcomes. In an effort to gather robust, quantitative insights into the factors that drive an effective and efficient site identification, selection, feasibility assessment, and activation process, Tufts Center for the Study of Drug Development (CSDD) conducted an in-depth survey of biopharmaceutical and CRO organizations.14 The START (Start-up Time And Readiness Tracking) II Study, conducted in early 2017 consisted of 591 individual respondents (313 from sponsors, 139 from CROs) from 403 unique organizations represented.

    The study yielded some very interesting insights regarding the current state of the industry:
    • Overall, CROs report completing all site related activities 6-11 weeks faster than sponsors – cycle times working with repeat sites are approximately 6 weeks faster, and approximately 11 weeks faster when working with new sites. Note that research suggests that 30% of sites selected for a typical multi-center study are new;15 
    • CROs report shorter cycle times across all individual tasks as well (site identification, site selection and overall study startup);
    • CROs report making greater investments in technology than do sponsors and report slightly greater levels of satisfaction with their processes than do sponsors; and
    • Overall sponsors and CROs have generally consistent views in terms of areas of improvement
    What do the results of this research tell us about CRO consolidation and whether it is good for the industry? CRO companies outperform sponsors and the most consistent performers also invest more in technology. The data supports the notion that CROs are investing more heavily into study startup technologies that in turn are fueling a faster and more efficient study startup process for clinical trials.  

    Conclusion
    The CRO consolidation phenomenon will likely continue into the foreseeable future with large CROs acquiring smaller, boutique CROs known for their regulatory and therapeutic focus. While CRO M&As can contribute in a significant way towards improving clinical trials, mergers in any industry are difficult to undertake, especially in terms of cultural differences, IT and tax considerations involved in consolidating international enterprises.

    Research from Tufts CSDD shows technology adoption in the CRO market continues to rise, making these players important innovators in the R&D value chain. That said, CRO mergers are likely to affect the agility and speed of operations and may hamper efforts to bring in new technologies. Nevertheless, when integrated effectively, CRO mergers can add significant value to both the pharmaceutical industry and the patients who depend on the life-saving medicines it produces.

    References
    1. “Cost to Develop and Win Marketing Approval for a New Drug Is $2.6 Billion,” Tufts CSDD Press Release, November 18th, 2014. Available at: http://csdd.tufts.edu/news/complete_story/pr_tufts_csdd_2014_cost_study
    2. “InVentiv Health, INC Research merger creates top 3 CRO,” BioPharmaDIVE, May 11, 2017. Jacob Bell. Available at: http://www.biopharmadive.com/news/inventiv-health-inc-merger-cro-manufacturing/442550/
    3. “Quintiles and IMS Health to Combine in ‘Merger of Equals’,” New York Times, May 3, 2016. Chad Bray. Available at: https://www.nytimes.com/2016/05/04/business/dealbook/quintiles-and-ims-health-to-combine-in-merger-of-equals.html
    4. “On Site: QuintilesIMS to Buy DrugDev,” Journal of Clinical Research Best Practices, Vol. 13, No. 7, July 2017. Available at: http://www.firstclinical.com/journal/2017/1707_OnSite81.pdf
    5. “PPD Acquires Acurian,” CenterWatch, August 27, 2013. Available at: https://www.centerwatch.com/news-online/2013/08/27/ppd-acquires-acurian/
    6. “LabCorp Completes Acquisition of Covance,” BusinessWire, February 19th, 2015.  Available at: http://www.businesswire.com/news/home/20150219005757/en/LabCorp-Completes-Acquisition-Covance
    7. “LabCorp just signed a billion-dollar deal for a healthcare company you’ve probably never heard of,” Business Insider, July 31st, 2017. Lydia Ramsey.  Available at: http://www.businessinsider.com/labcorp-acquires-chiltern-ma-in-contract-research-organizations-2017-7
    8. “Amulet Capital Partners, LP Announces Acquisition of SynteractHCR,” Business Wire, May 25, 2016. Available at: http://www.businesswire.com/news/home/20160525006356/en/Amulet-Capital-Partners-LP-Announces-Acquisition-SynteractHCR
    9. Available at: https://www.parexel.com/company/news-events/press-releases/2017/parexel-international-enters-definitive-agreement-be-acquired-pamplona-capital-management-8810-share-cash
    10. “PRA Health Sciences to acquire Symphony Health Solutions,” CenterWatch, August 10th, 2017. Available at: https://www.centerwatch.com/news-online/2017/08/10/pra-health-sciences-acquire-symphony-health-solutions/
    11. Available at: https://www.isrreports.com/reports/2017-edition-of-the-cro-market-size-projections-2016-2021/
    12. “Private Equity Opportunities in Contract Research Organizations (CROs): Part I,” The Healthcare Investor, August 30th, 2012. Amber Walsh. Available at: http://www.thehealthcareinvestor.com/2012/08/articles/healthcare-services-investing/private-equity-opportunities-in-contract-research-organizations-cros-part-i/
    13. “Merck Serono and Quintiles Announce Innovative Clinical Development Partnership,” BusinessWire, May 15th, 2013. Available at: http://www.businesswire.com/news/home/20130515005861/en/Merck-Serono-Quintiles-Announce-Innovative-Clinical-Development
    14. Webinar available at: http://xtalks.com/thankyou-17q057gobalto.ashx
    15. “Removing the Blinders in Site Selection,” goBalto, August 3rd, 2016. Craig Morgan. Available at: https://www.gobalto.com/hubfs/docs/ArtReprint_11aug_ANP.pdf?t=1504911760804

    Craig Morgan is a technology and life sciences management professional with more than 15 years experience in the application of informatics and bioinformatics to drug discovery. He currently heads up the marketing and brand development functions at goBalto, working with sponsors, CROs and sites to reduce cycle times and improve collaboration and oversight in clinical trials.
    Related Searches
    • Manufacturing
    • clinical development
    • Contract Research
    • patients
    Suggested For You
    The Future of Clinical Trials Series: Part II The Future of Clinical Trials Series: Part II
    The Future of Clinical Trials Series: Part I The Future of Clinical Trials Series: Part I
    Metrion, LifeArc Extend Neuroscience Alliance Metrion, LifeArc Extend Neuroscience Alliance
    Virtual Clinical Trials: The Future of Dermatology Studies Virtual Clinical Trials: The Future of Dermatology Studies
    Bioclinica Partners with Ikcon Pharma Bioclinica Partners with Ikcon Pharma
    Capricor, Lonza Enter CAP-1002 Development Agreement Capricor, Lonza Enter CAP-1002 Development Agreement
    Irisys Receives NIH Contract for the Formulation of Drinabant Irisys Receives NIH Contract for the Formulation of Drinabant
    Caprion-HistoGeneX Acquires Clinical Logistics Caprion-HistoGeneX Acquires Clinical Logistics
     Ionis Appoints Clinical Development EVP Ionis Appoints Clinical Development EVP
    The Slow – But Desperately Needed – Evolution of Oncology Clinical Development Designs The Slow – But Desperately Needed – Evolution of Oncology Clinical Development Designs
    Bioclinica Acquires Saliency Bioclinica Acquires Saliency
    Parexel Appoints Chief Patient Officer Parexel Appoints Chief Patient Officer
    Fujifilm to Invest $40M in New Facility Fujifilm to Invest $40M in New Facility
    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021 The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    Samsung Biologics Continues to Leverage Digitalization to Optimize Client Experience Samsung Biologics Continues to Leverage Digitalization to Optimize Client Experience

    Related Features

    • Clinical Trials | Information Technology | R&D
      Decentralized Trials Fuel AI Revolution in Clinical Research

      Decentralized Trials Fuel AI Revolution in Clinical Research

      The life sciences industry is giving clinical a full makeover, dramatically improving how new therapeutics are developed.
      Nick Moss, Vice President of Analytics and Machine Learning, Medable 11.17.20

    • Drug Development | Drug Discovery | R&D
      R&D Outsourcing Trends

      R&D Outsourcing Trends

      Highly specialized drug products and capacity needs drive increased reliance on contract service providers.
      Kristin Brooks, Managing Editor, Contract Pharma 10.14.20

    • Clinical Trials | R&D
      Improving Pharma R&D Efficiency: The need to transform clinical trials

      Improving Pharma R&D Efficiency: The need to transform clinical trials

      Cost pressures on drug development are driving the search for savings and efficiencies—but efforts need to be integrated if t
      ICON plc 10.10.18


    • Drug Development | Information Technology | R&D
      CRO Industry Update: Big Data Drives Drug Development Efforts

      CRO Industry Update: Big Data Drives Drug Development Efforts

      With growth in virtual trials and RWE, the clinical development landscape may never look the same
      Kristin Brooks, Managing Editor 05.11.18

    • R&D
      A Blueprint to Unify Clinical Operations

      A Blueprint to Unify Clinical Operations

      Fast-growing clinical research organization speeds study execution and improves quality
      Jim Reilly, VP of Clinical Market Strategy, Veeva Systems 05.08.18

    • R&D
      Newsmakers: Charles River

      Newsmakers: Charles River

      Charles River Expands
      Kristin Brooks, Managing Editor 05.07.18


    • R&D
      Streamlining Operations:  Sponsor-CRO Partnership Trends

      Streamlining Operations: Sponsor-CRO Partnership Trends

      Clinical teams have the opportunity to shed decades-old siloed operating model.
      Jim Reilly, Veeva Systems 09.06.17

    • R&D
      Social Responsibility in Action

      Social Responsibility in Action

      Transformation of strategic partnerships between CROs and sponsors
      Andrew MacGarvey, CEO, CROS NT 06.06.17

    • Analytical Services | Bioanalytical Services | R&D
      CROs & Next-Gen  Drug Development

      CROs & Next-Gen Drug Development

      R&D trends drive outsourcing in today’s market
      Kristin Brooks, Contract Pharma 05.09.17


    • R&D
      When Quality Meets Confidence

      When Quality Meets Confidence

      A look at global account management for R&D outsourcing
      Dr. Fadia AlKhalil, Vice President of Global Business Development for Laboratory Services, SGS 11.09.16

    • Clinical Trials | Drug Development | Preclinical Outsourcing | R&D
      CROs and Today’s  R&D Landscape

      CROs and Today’s R&D Landscape

      John Lewis of ACRO discusses opportunities, challenges, and the future CRO
      Kristin Brooks, Associate Editor, Contract Pharma 11.09.16

    • Analytical Services | Drug Development | Drug Discovery | Preclinical Outsourcing | R&D
      The Human Parts of Mouse Models

      The Human Parts of Mouse Models

      The PDX model system has come back into focus
      Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company 10.11.16


    • Analytical Services | Bioassay Development | Clinical Trials | Preclinical Outsourcing | R&D
      Robust Assay Designs

      Robust Assay Designs

      Easing the transition from preclinical to clinical research
      Tim Wright, Editor, Contract Pharma 10.11.16

    • Clinical Trials | Drug Development | R&D
      Optimizing Collaboration Effectiveness in Alliance Partnerships

      Optimizing Collaboration Effectiveness in Alliance Partnerships

      ...
      Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz 01.28.16

    • Biologics, Proteins, Vaccines | Biosimilars | cGMP Manufacture | Clinical Trials | Drug Delivery | Drug Development | Drug Discovery | Facilities | Formulation Development | GMPs/GCPs | Information Technology | Preclinical Outsourcing | QA/QC | R&D | Regulatory Affairs
      Top 25 Pharma and Biopharma Report

      Top 25 Pharma and Biopharma Report

      (Based on 2014 Sales, in $U.S. Millions)
      07.20.15

    Trending
    • Lonza To Exit Pharma Softgels And Liquid-Filled Hard Capsules
    • Roche Canada To Invest $500M To Create 500 Jobs In Ontario
    • Grifols Begins COVID-19 Plasma Treatment Trial
    • Fujifilm To Invest $2B In US Manufacturing Site
    • Virtual Clinical Trials: The Future Of Dermatology Studies
    Breaking News
    • Bone Therapeutics, Rigenerand Ink Cell Therapy Deal
    • NovaQuest Private Equity Acquires CoreRx
    • JS Bio and Etta Biotech Advancing Partnership
    • Intravacc Completes Project for Provention Bio’s Vax Candidate
    • Lonza to Exit Pharma Softgels and Liquid-Filled Hard Capsules
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    BGG Obtains U.S. Patent on AstaZine Natural Astaxanthin for Heart Function During Exercise
    Qualitas Health/iwi Raises $10 Million in Investment Round
    Aker BioMarine Expands Krill Portfolio with Novel Protein Hydrolysate
    Coatings World

    Latest Breaking News From Coatings World

    IGL Coatings Launches Graphene Reinforced Dual System Ceramic Coating
    Miller Paint Declares Simple Serenity its 2021 Color of the Year
    TAUBMANS Paint by PPG Releases ‘Chromatic Joy’ Palettes
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    CHF Solutions Appoints CEO
    Freehand Partners with Imperial Medial Solutions
    Intersect ENT Announces CMS Approval of Coding Application for Sinus Implant
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Bone Therapeutics, Rigenerand Ink Cell Therapy Deal
    NovaQuest Private Equity Acquires CoreRx
    JS Bio and Etta Biotech Advancing Partnership
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Marino Belotti Presents New Website
    Essence Cosmetics Expands in the U.S.
    Sigma Beauty Launches 'Brush Care' Sets at Sephora
    Happi

    Latest Breaking News From Happi

    Mix:Bar Launches at Target
    Crystal Deodorant Unveils Magnesium-Enriched Sticks
    Euromonitor Reveals Top 10 Global Consumer Trends for 2021
    Ink World

    Latest Breaking News From Ink World

    Cowan Graphics Adds Fujifilm Inca OnsetX3 HS
    Packaging Printing Market Worth $433.4 Billion by 2025: MarketsandMarkets
    O-I Foundation Gifts $50k to Facilitate COVID-19 Vaccine Access
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Domino grows installation and service teams
    ABG keeps pace with demand with recruitment drive
    Acucote expands FSC-certified portfolio
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Honeywell Delivered 225 Million Masks in December
    Techtextil, Texprocess Postponed to 2022
    Super Strong Inks Survive Tough Environments
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Bioventus Appoints SVP of Operations
    DePuy Synthes Receives 510(k) FDA Clearance for VELYS Robotic-Assisted Solution
    OrthoPediatrics Expands Agent Network in Three European Countries
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    UDC Subsidiary Adesis' Website Wins 2020 MarCom Platinum Award
    Roadsimple Modernizes Warehouse Ops with Zebra Technologies
    Graphene Flagship Launches Redesigned Website

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login